Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 9/20 | 0.57 |
| ▸ | PDE6D | O43924 | 1/20 | 0.54 |
| ▸ | PDE6A | P16499 | 1/20 | 0.54 |
| ▸ | PDE6G | P18545 | 1/20 | 0.54 |
| ▸ | PDE6B | P35913 | 1/20 | 0.54 |
| ▸ | PDE6C | P51160 | 1/20 | 0.54 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30727480 | 1.00 | PDE5A (0.57) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16816274 | 0.94 | PDE5A (0.49) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16137821 | 0.91 | POLB (0.48) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16816516 | 0.89 | POLB (0.47) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16816248 | 0.89 | PDE5A (0.52) | PDE5APDE10A | |
| SCHEMBL17013499 | 0.87 | MAPT (0.48) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16848002 | 0.87 | PDE5A (0.48) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16345647 | 0.87 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL4976195 | 0.87 | PDE5A (0.62) | PDE5APDE6DPDE6APDE6GPDE6B | |
| SCHEMBL16816784 | 0.86 | MAPT (0.46) | PDE5AMEN1POLBTHRBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | claimed |
| CN-108658872-B | Preparation method of avanafil intermediate | WUXI FURTHER PHARMACEUTICAL Co.,Ltd. (CN) | 2021-06-22 | — | — | CN | claimed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| WO-2015001567-A1 | PROCESS FOR THE PREPARATION OF (S)-4-[(3-CHLORO-4-METHOXYBENZYL)AMINO]-2-[2- (HYDROXYMETHYL)-1-PYRROLIDINYL]-N-(2-PYRIMIDINYL METHYL-5-PYRIMIDINE CARBOXAMIDE | MSN LABORATORIES PRIVATE LIMITED (IN) | 2015-01-08 | — | — | WO | claimed |
| CN-117430591-A | Synthesis method of avanafil | 康普药业股份有限公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-113880817-A | Avanafil impurity D and synthesis method and application thereof | 嘉实（湖南）医药科技有限公司 | 2022-01-04 | — | — | CN | disclosed |
| CN-108658872-B | Preparation method of avanafil intermediate | WUXI FURTHER PHARMACEUTICAL Co.,Ltd. (CN) | 2021-06-22 | — | — | CN | disclosed |
| CN-108658872-B | Preparation method of avanafil intermediate | WUXI FURTHER PHARMACEUTICAL Co.,Ltd. (CN) | 2021-06-22 | — | — | CN | disclosed |
| CN-111297868-A | Use of a composition comprising a heterocyclic compound for the manufacture of a medicament for the treatment of phosphodiesterase mediated diseases | 黄泳华 | 2020-06-19 | — | — | CN | disclosed |
| EP-2980087-B1 | PRODRUGS OF BICYCLIC SUBSTITUTED PYRIMIDINE TYPE PDE-5 INHIBITORS | XUANZHU PHARMA CO LTD (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-2980087-B1 | PRODRUGS OF BICYCLIC SUBSTITUTED PYRIMIDINE TYPE PDE-5 INHIBITORS | XUANZHU PHARMA CO LTD (CN) | 2018-06-06 | — | — | EP | disclosed |
| EP-2886540-B1 | BICYCLIC SUBSTITUTED PYRIMIDINE COMPOUNDS | XUANZHU PHARMA CO LTD (CN) | 2017-07-26 | — | — | EP | disclosed |
| US-6656935-B2 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-02 | — | — | US | disclosed |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-10-16 | — | — | US | disclosed |
| CN-1440393-A | cyclic compound | TANABE SEIYAKU CO (JP) | 2003-09-03 | — | — | CN | disclosed |
| EP-1316316-A1 | PREPARATIONS FOR ORAL ADMINISTRATION | TANABE SEIYAKU CO., LTD. (JP) | 2003-06-04 | — | — | EP | disclosed |
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
| CN-1374953-A | 6-membered aromatic ring compound containing nitrogen | TANABE SEIYAKU CO (JP) | 2002-10-16 | — | — | CN | disclosed |
| EP-1219609-A1 | AROMATIC NITROGENOUS SIX-MEMBERED RING COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2002-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032647-A1 | Treatment of penile erectile dysfunction, pulmonary hypertension, and diabetic gastroparesis | PDE3A, PDE3B, PDE2A | PDE5A 4/4885PDE6D 55/4885PDE6A 36/4885 |
| US-20030195220-A1 | A tablet has an acid, with reduced solubility in the neutral and alkaline regions, is used for treating sexual disorders erectile dysfunction | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6D 28/4885PDE6A 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.